explore -WSS

explore

author：hotspot 2025-08-23 08:52:35 - browse：4

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

WSS

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Why Medicare shouldn’t cover every FDA

Psilocybin's anti

Wegovy leads to weight loss. Can it treat depression, too?

New clues to why women have higher risk of autoimmune disorders

How generative AI ratchets up security threats for health systems

hotspot

explore

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why you shouldn’t ask, “What country has the best health care?”

Affirmative action in medical school literally saved lives

Radiation, mainstay of cancer treatment, begins a fade

Malaria cases in Florida and Texas: Here’s what you need to know

Merck, Johnson & Johnson CEOs will testify on high drug prices

As demand for Covid shots wanes, Moderna seeks its next success

Reconstructing family trees of blood cells may help predict disease

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare drug price negotiation legal challenge met with skepticism

Wikipedia

How to make Best Hospitals ratings actually useful for patients

Philips to halt sales of sleep apnea machines in U.S.

How to make AI work for medicine

Pancreatic cancer early detection could be helped by AI

Neuroscience startup Neumora files for IPO

Boston competes with Raleigh

focus

hotspot

entertainment

focus